XML 46 R33.htm IDEA: XBRL DOCUMENT v3.20.1
FAIR VALUE MEASUREMENTS (Details)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2010
USD ($)
item
$ / shares
Mar. 31, 2020
USD ($)
payment
item
Dec. 31, 2019
USD ($)
Fair Value Measurement [Line Items]      
Cumulative liability   $ 19.5 $ 19.3
Manhattan and Ariston Pharmaceuticals Merger [Member]      
Fair Value Measurement [Line Items]      
Notes Issued $ 15.5    
Debt instrument, term 5 years    
Det instrument rate 5.00%    
Debt Instrument convertible conversion price | $ / shares $ 1,125    
Percentage of cash proceeds from operation to repay convertible debt 50.00%    
Number of obligations | item 0    
Convertible Notes Payable [Member]      
Fair Value Measurement [Line Items]      
Det instrument rate 5.00% 5.00% 5.00%
Debt Instrument convertible conversion price | $ / shares $ 1,125    
Percentage of cash proceeds from operation to repay convertible debt 50.00%    
Number of obligations | item   0  
Cumulative liability   $ 19.5 $ 19.3
Number of payments | payment   0